These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11122017)

  • 1. Treatment of psoriasis with oral liarozole: a dose-ranging study.
    Berth-Jones J; Todd G; Hutchinson PE; Thestrup-Pedersen K; Vanhoutte FP
    Br J Dermatol; 2000 Dec; 143(6):1170-6. PubMed ID: 11122017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
    Bhushan M; Burden AD; McElhone K; James R; Vanhoutte FP; Griffiths CE
    Br J Dermatol; 2001 Oct; 145(4):546-53. PubMed ID: 11703279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole.
    Dockx P; Decree J; Degreef H
    Br J Dermatol; 1995 Sep; 133(3):426-32. PubMed ID: 8546999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral liarozole in the treatment of patients with moderate/severe lamellar ichthyosis: results of a randomized, double-blind, multinational, placebo-controlled phase II/III trial.
    Vahlquist A; Blockhuys S; Steijlen P; van Rossem K; Didona B; Blanco D; Traupe H
    Br J Dermatol; 2014 Jan; 170(1):173-81. PubMed ID: 24102348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral liarozole vs. acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study.
    Verfaille CJ; Vanhoutte FP; Blanchet-Bardon C; van Steensel MA; Steijlen PM
    Br J Dermatol; 2007 May; 156(5):965-73. PubMed ID: 17263800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study.
    Ludbrook VJ; Hicks KJ; Hanrott KE; Patel JS; Binks MH; Wyres MR; Watson J; Wilson P; Simeoni M; Schifano LA; Reich K; Griffiths CE
    Br J Dermatol; 2016 May; 174(5):985-95. PubMed ID: 26785220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm
    Mrowietz U; Szepietowski JC; Loewe R; van de Kerkhof P; Lamarca R; Ocker WG; Tebbs VM; Pau-Charles I
    Br J Dermatol; 2017 Mar; 176(3):615-623. PubMed ID: 27515097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
    Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
    Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.
    Papp K; Pariser D; Catlin M; Wierz G; Ball G; Akinlade B; Zeiher B; Krueger JG
    Br J Dermatol; 2015 Sep; 173(3):767-76. PubMed ID: 25704750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial.
    Yao DN; Lu CJ; Wen ZH; Yan YH; Xuan ML; Li XY; Li G; He ZH; Xie XL; Deng JW; Guo XF; Ou AH
    Trials; 2016 Mar; 17(1):140. PubMed ID: 26983642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of oral liarozole on epidermal proliferation and differentiation in severe plaque psoriasis are comparable with those of acitretin.
    Kuijpers AL; Van Pelt JP; Bergers M; Boegheim PJ; Den Bakker JE; Siegenthaler G; Van de Kerkhof PC; Schalkwijk J
    Br J Dermatol; 1998 Sep; 139(3):380-9. PubMed ID: 9988537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis: a prospective, randomized, double-blind, dose-ranging study.
    Dogra S; Krishna V; Kanwar AJ
    Clin Exp Dermatol; 2012 Oct; 37(7):729-34. PubMed ID: 22830389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical becocalcidiol for the treatment of psoriasis vulgaris: a randomized, placebo-controlled, double-blind, multicentre study.
    Helfrich YR; Kang S; Hamilton TA; Voorhees JJ
    Br J Dermatol; 2007 Aug; 157(2):369-74. PubMed ID: 17596167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator.
    Barker JN; Ashton RE; Marks R; Harris RI; Berth-Jones J
    Br J Dermatol; 1999 Aug; 141(2):274-8. PubMed ID: 10468799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study.
    Nemoto O; Hirose K; Shibata S; Li K; Kubo H
    Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
    Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
    Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.